share_log
Moomoo 24/7 ·  Mar 11 07:14
Monte Rosa Therapeutics Announced MRT-8102 Is Expected To Be Developed For Inflammatory Diseases Driven By Interleukin-1β And The NLRP3 Inflammasome. This Is The First Development Candidate To Be Declared From The Company's NEK7 Development Program
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment